Tracleer licence extension

The licence for Tracleer (bosentan) has been extended to include use for the reduction of the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Treatment should be initiated at a dose of 62.5mg twice daily for four weeks and then increased to a maintenance dose of 125mg twice daily.

View Tracleer drug record

Further information: Actelion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Elleste Duet, Elleste Solo, Diprosone and Livial.

Potentially addictive medicines 'being prescribed for years'

Potentially addictive medicines 'being prescribed for years'

Hundreds of thousands of people are receiving prescriptions...

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.